Paper
0
De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy
Authors
Published
Jun 1, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.